Dr Ghanshyam Ghelani | Bladder Cancer | Best Researcher Award
SUNY Upstate Medical University | United States
Author Profile
๐ฉบGhanshyam Ghelani, MD ๐
Hematology-Oncology Fellow & Clinical Investigator
SUNY Upstate Medical University, Syracuse, NY
๐ Education
- M.B.B.S. โ B.J. Medical College, Ahmedabad, Gujarat, India (09/2002 โ 03/2008)
๐ Ranked in the top 10% of a class of 250 students. - Internal Medicine Residency โ The Wright Center for Graduate Medical Education, Scranton, PA, USA (07/2013 โ 06/2016)
๐ฅ Completed residency at affiliate hospitals including Geisinger CMC and VA Medical Center.
๐ Awarded M.D. by New York State on November 16, 2016. - Hematology-Oncology Fellowship โ SUNY Upstate Medical University, Syracuse, NY (07/2021 โ 06/2024)
๐ Active Member of the Transfusion Medicine Committee and Hematology-Oncology Representative of the Resident and Fellow Forum.
๐ผ Certifications and Licensure
- Board Certification โ The American Board of Internal Medicine
- State License โ New York: Full License # 285166
- DEA Registration โ FG6123385
- Advanced Cardiac Life Support (ACLS) โ Re-Certified on 10/09/2021
๐ Professional Memberships
- ๐จโโ๏ธ Member, American College of Physicians
- ๐ฎ๐ณ Life Member, Gujarat Medical Council
- ๐ฉบ Member, American Medical Association (AMA)
- ๐งฌ Member, American Society of Clinical Oncology (ASCO)
- ๐ Member, European Society for Medical Oncology (ESMO)
- ๐ฉธ Member, American Society of Hematology (ASH)
๐ฌ Research and Academic Work
Assistant Professor of Medicine & Clinical Investigator
SUNY Upstate Medical University (07/2016 โ 06/2021)
- Key Research Projects
- ๐งฌ HPV-Positive Clinically Advanced Bladder Squamous Cell Carcinoma (aBSCC): Analyzed genomic alterations associated with HPV.
- ๐งโ๐ฌ Metabolic Syndrome & Immunotherapy in NSCLC: Studied the impact of metabolic syndrome on outcomes with immune checkpoint inhibitors in non-small cell lung cancer (NSCLC).
- ๐ฉธ Peripheral Blood Biomarkers in Metastatic Melanoma: Identified biomarkers for treatment response and immune-related adverse events in patients treated with immunotherapy for stage-IV melanoma.
๐ Awards
- Ranked in the top 10% of the class during medical school. ๐๏ธ
Dr. Ghanshyam Ghelani is a dedicated Hematology-Oncology fellow with expertise in internal medicine and a strong background in cancer research, particularly in genomic profiling, immunotherapy, and biomarker discovery. ๐งฌ๐ก
Dr. Ghanshyam Ghelani is a highly accomplished medical professional, currently advancing his expertise as a Hematology-Oncology Fellow at SUNY Upstate Medical University. With a strong foundation in internal medicine and an impressive portfolio of research in cancer treatment and immunotherapy, Dr. Ghelani has made significant contributions to the field of oncology. His active involvement in professional societies and dedication to exploring novel cancer therapies highlight his commitment to improving patient outcomes through cutting-edge research and clinical practice. Dr. Ghelani’s journey reflects a deep passion for medicine, research, and innovation in cancer care. ๐๐งฌ๐
๐๐ฌNOTABLE PUBLICATION:
-
- Radioimmunoconjugates in the Age of Modern Immuno-Oncology
- Authors: Nasr, D., Kumar, P.A., Zerdan, M.B., Graziano, S., Lim, S.H.
- Journal: Life Sciences
- Year: 2022
- HPV-Positive Clinically Advanced Squamous Cell Carcinoma of the Urinary Bladder (aBSCC): A Comprehensive Genomic Profiling (CGP) Study
- Authors: Ghelani, G.H., Zerdan, M.B., Jacob, J., Bratslavsky, G., Basnet, A.
- Journal: Urologic Oncology: Seminars and Original Investigations
- Year: 2023
- Breast Cancer Treatment: To Target or Not? That Is the Question
- Authors: Stone, A., Lin, K.M., Ghelani, G.H., Graziano, S., Kotula, L.
- Journal: Cancers
- Year: 2023
- Hematologic Abnormalities After COVID-19 Infection: A Case of Coombs-Negative Hemolytic Anemia and Thrombocytopenia
- Authors: Siegenthaler, A.G., Ghelani, G., Brady, A., Loon, T., Madhira, B.R.
- Journal: Journal of Investigative Medicine High Impact Case Reports
- Year: 2023
- Metabolic Syndrome Is Independently Associated with Improved Overall Survival to First-Line Therapy with Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
- Authors: Bou Zerdan, M., Ashok Kumar, P., Barrios, D.M., Graziano, S., Lim, S.H.
- Journal: Frontiers in Oncology
- Year: 2023
- Radioimmunoconjugates in the Age of Modern Immuno-Oncology